Accueil > Événements > Séminaires

Série de Séminaires Biologie Biochimie

NanoSystems for biology & therapeutics

Prof. Fuyuhiko Tamanoi (California NanoSystems Institute & UCLA Department of Microbiology, Immunology & Molecular Genetics, USA)

publié le , mis à jour le

Cinq séminaires du Mardi 15 juin au lundi 21 Juin 2010, chaque jour à 14h
UM2, Salle de Cours SC-25.01
Ces cinq conférences peuvent être suivies indépendamment les unes des autres.


1. Mardi 15 Juin 2010 à 14h
Nanoparticles/cell Interface, cellular Uptake, delivery, targeting

2. Mercredi 16 Juin 2010 à 14h
Nanoparticles, siRNA/miRNA

3. Jeudi 17 Juin 2010 à 14h
Nanoparticles, mouse experiments

4. Vendredi 18 Juin 2010 à 14h
Inhibitors of protein Geranylgeranyltransferases, chemical biology

5. Lundi 21 Juin 2010 à 14h
Signal transduction/MTOR/mTOR inhibitors


Cancer Nanotherapy. Biocompatibility, biodistribution and drug delivery efficacy of mesoporous silica nanoparticles in animals

Mesoporous silica nanoparticles (MSNs) are a promising material for drug delivery. At UCLA, we have been developing a variety of nanoparticles including mechanized MSNs equipped with nanovalves and nanoimpellers to achieve controlled released of anticancer drugs. In this talk, I will first describe some of these nanoparticles. I will then discuss our recent animal experiments that showed that MSNs are well tolerated and rapidly excreted when injected into mice. Our study involves serological, hematological and histopathological examinations of mouse tissues after MSN injection. Biodistribution study using human cancer xenografts in vivo imaging as well as fluorescent microscope imaging, inductively coupled plasma mass spectroscopy showed that MSNs preferentially accumulate in tumors. Finally, tumor suppressing capability of camptothecin loaded MSNs was demonstrated by following growth of tumors. Our study uncovered outstanding features of MSNs that suggest advantages for using these nanomaterials for cancer nanotherapy.

About the lecturer

Prof. Fuyuhiko Tamanoi is a biochemist who has served on the University of California, Los Angeles (UCLA) School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993, where he then became a full professor in 1997. Since 1996, he has been a Director of Signal Transduction Program Area at Jonsson Comprehensive Cancer Center. In 2002 he joined joined the California NanoSystems Institute (CNSI), of which he is now the Research Director (since 2008).

Dr. Tamanoi earned his B.S. and M.S. in Biochemistry at the University of Tokyo. He received PhD in Molecular Biology at Nagoya University (Japan) in 1977. He was a postdoctoral fellow at Harvard Medical School (USA), where he worked on bacteriophage DNA replication. From 1980 to 1985, he was a senior staff investigator at Cold Spring Harbor Laboratory (New-York), where he worked on adenovirus DNA replication. From 1985 to 1993, he was an Assistant Professor and then Associate Professor at the University of Chicago, where he initiated studies on lipid modification of the Ras family proteins.

Prof. Tamanoi’s current laboratory research at UCLA and CNSI, focuses on signal transduction and signal transduction inhibitors. He is currently exploring ways to deliver signal transduction inhibitors using nanoparticles, as well as the nanodelivery of novel anti-cancer drugs.

Cf. Prof. Tamanoi’s webpages at UCLA MIMG and at CNSI.


Contact à Montpellier : les personnes souhaitant rencontrer le Prof. Tamanoi durant son séjour à Montpellier, sont invitées à contacter sans tarder Jean-Olivier Durand (ICGM UMR 5253).

N.B. Ces conférences font partie du cycle des séminaires de l’École Doctorale 459 Sciences Chimiques, tous les doctorants sont donc invités à y assister dans la mesure de leurs disponibilités.

Voir en ligne : Prof Tamanoi’s website (at MIMG Dept, UCLA)


Ajouter un événement iCal